MYnd Analytics and Emmaus Life Sciences Announce Availability of Definitive Joint Proxy Statement/Prospectus Relating to Merger and Spin-off Transaction

World News: . []

MISSION VIEJO, Calif. and TORRANCE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- , a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and , a leader in sickle cell disease treatment, announced today that the registration statement filed with the Securities and Exchange Commission (SEC), which includes the definitive joint proxy statement/prospectus of MYnd and Emmaus, was declared effective by the SEC on June 11, and companies intend to commence mailing to their stockholders on June 14.  The respective special stockholder meetings will be held on July 9, 2019 to consider approval of the proposed merger and spin-off transaction announced in January of this year.  The record date for each meeting is June 7, 2019.

INVESTORS AND SECURITY HOLDERS OF MYND AND EMMAUS ARE URGED TO CAREFULLY READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC BY MYND AND EMMAUS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Investors and security holders may obtain free copies of these documents at the SEC’s web site at or by contacting MYnd Investor Relations or Emmaus Investor Relations.

MYnd, Emmaus and their respective directors and executive officers may be deemed participants in the solicitation of proxies with respect to the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction is included in the joint proxy statement/prospectus described above.

MYnd Analytics, Inc. (), with its wholly owned subsidiary Arcadian Telepsychiatry Services, LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient’s unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services, LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd’s customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: .

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its lead prescription product, Endari, demonstrated positive clinical results in a completed Phase 3 clinical trial for sickle cell disease and received FDA approval in July 2017. Emmaus began marketing and selling Endari in the U.S. in January 2018. For more information, please visit www.emmauslifesciences.com.

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

For MYND: Crescendo Communications, LLC Tel: +1 (212) 671-1020 Email: mynd@crescendo-ir.com

For Emmaus: Joseph (Jay) C. Sherwood III Chief Financial Officer Tel: +1 (310) 214-0065, Ext. 3005Email: jsherwood@emmauslifesciences.com

Emmaus Investor Relations:PondelWilkinson Inc. Evan Pondel/Judy Sfetcu Tel: +1 (310) 279-5980Email:            

More news and information about MYnd Analytics, Inc.; Emmaus Life Sciences, Inc.

Published By:

Globe Newswire: 15:56 GMT Wednesday 12th June 2019

Published: .

Search for other references to "mynd" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us